# US 8,771,705 B2 · Combination of protein vaccine and mesenchymal stem cells for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,771,705 B2
- Document ID: US8771705B2
- Status: Granted
- Kind: B2
- Application number: 12/844,044
- Filed: 2010-07-27
- Published: 2011-02-03
- Granted: 2014-07-08
- Earliest claimed: 2009-07-30
- Assignees: Healthbanks Biotech Co., Ltd.; Kooper Biotech Co., Ltd.
- Applicants: Win-Ping Deng; Hsiu-Kang Chang; Hung-Chien Wei; Tsang-Hsien Alexander Wu
- Inventors: Win-Ping Deng; Hsiu-Kang Chang; Hung-Chien Wei; Tsang-Hsien Alexander Wu
- Web page: https://patentgrep.com/patent/US8771705B2

## CPC

- A61K 39/001114: {CD74, Ii, MHC class II invariant chain or MHC class II gamma chain}
- A61K 40/10: characterised by the cell type used
- A61K 40/4213: {CD74, Ii, MHC class II invariant chain or MHC class II gamma chain}
- A61K 40/46: Viral antigens
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2239/31: characterized by the route of administration
- C12N 2710/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method for inhibiting growth and/or metastasis of a tumor in a mammal is disclosed. The method comprises administering to a mammal in need thereof an effective amount of stem cells comprising a transgene encoding at least one oncogenic protein, wherein the stem cells are immortal and show no signs of neoplastic transformation; and administering to the mammal a vaccine composition comprising an effective amount of at least one immunogenic protein capable of eliciting at least one antibody specific against the at least one oncogenic protein, and thereby inhibiting growth and/or metastasis of a tumor in the mammal. A therapeutic kit for inhibiting growth and/or metastasis of a tumor in a mammal is also disclosed.

## Claims

### Claim 1

A method for inhibiting growth and/or metastasis of a cancer cell, cornprising:
administering to a mammal in need thereof an effective amount of mesenchymal stem cells comprising a transgene encoding human papillomavirus (HPV) oncogenic protein selected from the group consisting of HPV E7, HPV E6 and a combination thereof, wherein the mesenchymal stem cells are immortal and show no signs of neoplastic transformation;
administering to the mammal a vaccine composition comprising an effective amount of an immunogenic protein capable of eliciting an antibody specific against the HPV oncogenic protein selected from the group consisting of HPV E7, HPV E6 and a combination thereof;
wherein the mesenchymal stem cells fuse with the cancer cell in the mammal, and wherein the fusion results in the expression of the HPV oncogneic protein selected from the group consisting of HPV E7, HPV E6 and a combination thereof on the cancer cell in the mammal; and
wherein the antibody specific against the HPV oncogenic protein selected from the group consisting of HPV E7, HPV E6 and a combination thereof effects the death of the cancer cell expressing the HPV concogenic protein selected from the group consisting, of HPV E7, HPV E6 and a combination thereof in the mammal.

### Claim 2 (depends on 1)

The method of claim 1, wherein the immunogenic protein comprises at least one Major Histocompatihility Complex (MHC) class II epitope.

### Claim 3 (depends on 1)

The method of claim 1, wherein the elicited antibody triggers complement-dependent tumor cell lysis.

### Claim 4 (depends on 1)

The method of claim 1, wherein the stem cells and the vaccine composition are sequentially administered to the mammal.

### Claim 5 (depends on 1)

The method of claim 1, wherein the stem cells and the vaccine composition are concurrently administered, to the mammal.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mesenchymal stem cells are derived from bone marrow or cord blood.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cancer cell is at least one selected from the group consisting of a lung cancer cell and a sarcoma.

### Claim 8 (depends on 1)

The method of claim 1, wherein the mammal has metastatic cancer.

### Claim 9 (depends on 1)

The method of claim 1, wherein the immunogenic protein comprises it fusion protein comprising:
(a) a Psendomonas exotoxin A (PE) fragment comprising a binding domain and a translocation domain and without a cytotoxic domain;
(b) a human papillomavirus (HPV) Envelope protein selected from the group consisting of HPV E7, HPV E6, and a combination thereof; and
(c) a carboxyl terminal moiety comprising an endoplasmic retention sequence.